Semler Scientific Inc. has announced a new liquidity contract through a Controlled Equity Offering Sales Agreement with a consortium of financial institutions including Barclays Capital Inc., Cantor Fitzgerald & Co., Canaccord Genuity LLC, Needham & Company, LLC, Craig-Hallum Capital Group LLC, and Lake Street Capital Markets, LLC. The agreement allows for the issuance and sale of up to $500 million in common stock through an at-the-market $(ATM.UK)$ offering program. As of early June 2025, the company has already issued and sold over 3.5 million shares, generating net proceeds of approximately $136.2 million. This move is set to enhance liquidity and provide additional financial flexibility.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.